Blumentals W A, Gomez-Caminero A, Joo S, Vannappagari V
Worldwide Epidemiology, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA.
Int J Impot Res. 2004 Aug;16(4):350-3. doi: 10.1038/sj.ijir.3901174.
The association between erectile dysfunction (ED) and acute myocardial infarction (AMI) among men was examined in the Integrated Healthcare Information Services National Managed Care Benchmark Database (IHCIS). The IHCIS is a fully de-identified, HIPAA-compliant database and includes complete medical history for more than 17 million managed care lives; data from more than 30 US health plans, covering seven census regions; and patient demographics, including morbidity, age and gender. A total of 12,825 ED patients and an equal number of male patients without ED were included in the retrospective cohort study. Logistic regression analyses were performed to assess the adjusted risk of AMI that accounted for age at ED diagnosis, smoking, obesity and medications including ACE inhibitors, beta blockers and statins. The cohort of men with ED were observed to have a two-fold increase in the risk for AMI (OR=1.99, 95% CI=1.17, 3.38) after adjusting for age at ED diagnosis, smoking, obesity, and use of ACE inhibitors, beta blockers and statins. Some evidence of a possible trend toward increased risk was detected by age group. After controlling for the aforementioned covariates and compared to men 30-39 y of age, it was noted that patients 40-44 y of age were 3.8 times more likely to develop an AMI (OR=3.76, 95% CI=1.21, 11.7), 45- to 49-y-old men were also more than three times as likely to have an AMI (OR=3.14, 95% CI=1.03, 9.64), and 50- to 55-y-old patients had a four-fold increased risk of developing AMI (OR=4.04, 95% CI=1.39, 11.7). The risk becomes more pronounced with increasing age, indicating the need for cardiologists and internists to monitor ED patients who may not necessarily present with cardiovascular symptoms.
在综合医疗信息服务国家管理式医疗基准数据库(IHCIS)中,研究了男性勃起功能障碍(ED)与急性心肌梗死(AMI)之间的关联。IHCIS是一个完全去识别化、符合《健康保险流通与责任法案》(HIPAA)的数据库,包含超过1700万管理式医疗对象的完整病史;来自美国30多家健康计划的数据,覆盖七个普查区域;以及患者人口统计学数据,包括发病率、年龄和性别。在这项回顾性队列研究中,共纳入了12825例ED患者和同等数量的无ED男性患者。进行了逻辑回归分析,以评估在考虑ED诊断时的年龄、吸烟、肥胖以及包括血管紧张素转换酶抑制剂(ACE抑制剂)、β受体阻滞剂和他汀类药物在内的药物因素后,AMI的调整后风险。在对ED诊断时的年龄、吸烟、肥胖以及ACE抑制剂、β受体阻滞剂和他汀类药物的使用情况进行调整后,观察到患有ED的男性队列发生AMI的风险增加了两倍(比值比[OR]=1.99,95%置信区间[CI]=1.17,3.38)。按年龄组检测到了风险可能增加的一些趋势证据。在控制上述协变量后,与30 - 39岁的男性相比,发现40 - 44岁的患者发生AMI的可能性高3.8倍(OR=3.76,95% CI=1.21,11.7),45 - 49岁的男性发生AMI的可能性也高出三倍多(OR=3.14,95% CI=1.03,9.64),50 - 55岁的患者发生AMI的风险增加了四倍(OR=4.04,95% CI=1.39,11.7)。风险随着年龄增长而更加明显,这表明心脏病专家和内科医生需要对不一定有心血管症状的ED患者进行监测。